About Ultragenyx
Ultragenyx is a company based in Novato (United States) founded in 2010 was acquired by Royalty Pharma in December 2019.. Ultragenyx has raised $135.1 million across 3 funding rounds from investors including Takeda Pharmaceuticals, Royalty Pharma and TPG. The company has 1,290 employees as of December 31, 2024. Ultragenyx has completed 2 acquisitions, including Dimension Therapeutics and GeneTx. Ultragenyx offers products and services including DTX401, DTX301, UX701, UX143, and GTX-102. Ultragenyx operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Novato, United States
- Employees 1290 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Ultragenyx Pharmaceutical Inc.
-
Annual Revenue
$560.23 M29.01as on Dec 31, 2024
-
Net Profit
$-569.18 M6.17as on Dec 31, 2024
-
EBITDA
$-500.43 M7.87as on Dec 31, 2024
-
Total Equity Funding
$135.1 M (USD)
in 3 rounds
-
Latest Funding Round
$75 M (USD), Series B
Dec 31, 2012
-
Investors
Takeda Pharmaceuticals
& 9 more
-
Employee Count
1290
as on Dec 31, 2024
-
Investments & Acquisitions
Dimension Therapeutics
& 1 more
-
Acquired by
Royalty Pharma
(Dec 18, 2019)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Ultragenyx
Ultragenyx is a publicly listed company on the NASDAQ with ticker symbol RARE in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Ultragenyx
Ultragenyx offers a comprehensive portfolio of products and services, including DTX401, DTX301, UX701, UX143, and GTX-102. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treatment for glycogen storage disease type Ia.
Therapy for ornithine transcarbamylase deficiency.
Treatment targeting Wilson disease.
Therapy for osteogenesis imperfecta.
Treatment for Angelman syndrome.
Unlock access to complete
Unlock access to complete
Leadership Team
237 people
Software Development Team
107 people
Operations Team
49 people
Senior Team
48 people
Product Management Team
43 people
Legal and Compliance
23 people
Ultracare Team
16 people
Human Resources and Administration
14 people
Unlock access to complete
Funding Insights of Ultragenyx
Ultragenyx has successfully raised a total of $135.1M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $75 million completed in December 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series B — $75.0M
-
First Round
First Round
(20 Jun 2011)
- Investors Count 9
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2012 | Amount | Series B - Ultragenyx | Valuation | Adage Capital Management | |
| Jul, 2012 | Amount | Series A - Ultragenyx | Valuation |
investors |
|
| Jun, 2011 | Amount | Series A - Ultragenyx | Valuation | F-Prime Capital , Healthcap |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Ultragenyx
Ultragenyx has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include Takeda Pharmaceuticals, Royalty Pharma and TPG. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Fund of funds focused on pre-seed and seed-stage companies
|
Founded Year | Domain | Location | |
|
Venture capital investment and global platform support for startups.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Ultragenyx
Ultragenyx has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Dimension Therapeutics and GeneTx. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Developer of a antisense oligonucleotide for treating a rare genetic disorder
|
2017 | ||||
|
Provider of gene therapy for rare diseases
|
2013 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Ultragenyx
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Ultragenyx Comparisons
Competitors of Ultragenyx
Ultragenyx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Ultragenyx
Frequently Asked Questions about Ultragenyx
When was Ultragenyx founded?
Ultragenyx was founded in 2010 and raised its 1st funding round 1 year after it was founded.
Where is Ultragenyx located?
Ultragenyx is headquartered in Novato, United States. It is registered at Novato, California, United States.
Is Ultragenyx a funded company?
Ultragenyx is a funded company, having raised a total of $135.1M across 3 funding rounds to date. The company's 1st funding round was a Series A of $45M, raised on Jun 20, 2011.
How many employees does Ultragenyx have?
As of Dec 31, 2024, the latest employee count at Ultragenyx is 1,290.
What is the annual revenue of Ultragenyx?
Annual revenue of Ultragenyx is $560.23M as on Dec 31, 2024.
What does Ultragenyx do?
The company was founded in 2010 and is headquartered in Novato, United States, within the biotechnology sector. Focus is placed on developing treatments for rare and ultra-rare metabolic disorders. Burosumab, a fully human monoclonal antibody, is indicated for X-linked hypophosphatemia and tumor-induced osteomalacia. rhGUS (UX003), a recombinant enzyme, is advanced for mucopolysaccharidosis 7, a lysosomal storage disease. Operations center on clinical-stage pipeline advancement for these conditions.
Who are the top competitors of Ultragenyx?
Ultragenyx's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
What products or services does Ultragenyx offer?
Ultragenyx offers DTX401, DTX301, UX701, UX143, and GTX-102.
Is Ultragenyx publicly traded?
Yes, Ultragenyx is publicly traded on NASDAQ under the ticker symbol RARE.
How many acquisitions has Ultragenyx made?
Ultragenyx has made 2 acquisitions, including Dimension Therapeutics, and GeneTx.
Who are Ultragenyx's investors?
Ultragenyx has 10 investors. Key investors include Takeda Pharmaceuticals, Royalty Pharma, TPG, T. Rowe Price, and Eight Roads Ventures.
What is Ultragenyx's ticker symbol?
The ticker symbol of Ultragenyx is RARE on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.